Agilent Technologies Inc vs JPMorgan Diversified Return International Eqty ETF — how do they compare? Agilent Technologies Inc trades at $148.42 (market cap $42.22B), while JPMorgan Diversified Return International Eqty ETF trades at $76.97. The key difference: Agilent Technologies Inc pays a 0.68% dividend while JPMorgan Diversified Return International Eqty ETF pays none, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, Agilent Technologies Inc nearer its low. Which is the better fit depends on your goals.
| A | JPIN | |
|---|---|---|
Market Cap | $42.22B | — |
Sector | Health | — |
52-Week High | $157.20 | $77.00 |
52-Week Low | $110.24 | $64.96 |
Enterprise Value | $43.77B | — |
Dividend Yield | 0.68% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $148.77, up 0.03% on the day, near its consensus price target of $154.90. The stock shows bullish technical signals with strong moving average support, though RSI indicates overbought conditions. Recent earnings beat expectations in Q1 2026, and the company maintains robust profitability with a 19.55% net income margin. Key developments include FDA and EU regulatory approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its biopharma portfolio.
Outlook remains positive with analyst consensus at Buy (77.5%) and a projected 4.1% upside to the price target. Risks include elevated valuation multiples (P/E 30.02) and dependence on healthcare sector growth. Earnings on August 26, 2026, will be critical for validating continued momentum amid competitive and macroeconomic pressures.
JPIN (JPMorgan Diversified Return International Equity ETF) trades at $76.97, up 0.8% with strong technical momentum as moving averages signal bullish conditions. The ETF provides broad exposure to foreign large-cap value stocks through a smart beta approach. Recent dividend activity shows a $0.91 distribution scheduled for June 2026, while technical indicators show mixed signals with RSI in overbought territory but ADX confirming strong trend strength.
The ETF's outlook remains positive given its diversified international exposure and value orientation, though investors face currency risk and emerging market volatility. Current technical strength suggests continued upward momentum, but overbought RSI levels indicate potential near-term consolidation. The fund's systematic approach to international value investing provides defensive characteristics in volatile markets.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →